🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against superbug strains of the infection, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting in excess of 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Results and Global Access

According to results released by a major medical journal, the new drug cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have shared positive views. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.